At the beginning of this year, Shanghai Pudong New Area released an action plan for the high-quality development of the biopharmaceutical industry, aiming to promote the scale of the biopharmaceutical industry to reach the 400 billion yuan mark through institutional innovation. Build a national-level strategic emerging industry base and a 100-billion-level advanced manufacturing cluster. It is estimated that by 2025, the scale of the new medicine and life health industry will exceed 540 billion yuan; the “Fujian Province’s Implementation Plan for Accelerating the High-quality Development of the Biomedical Industry” proposes, From 2022 to 2025, it is planned to arrange a provincial special fund of nearly 1 billion yuan to support the development of the biomedical industry. Zhang Wenyang, member of the party group and deputy director of the Fujian Provincial Development and Reform Commission, said that by 2025, the province’s pharmaceutical industry’s operating income will strive to reach 120 billion yuan, creating a group of leading backbone enterprises, key innovative products, technology research and development and public service platforms and characteristic industries cluster.Medical companies such as Ningbo ALPS will participate.
A booming industry attracts capital competition. In 2021, there will be 121 new listed companies in my country’s biomedical field, a year-on-year increase of over 75%; nearly 1,900 financing events have occurred in the biomedical field, and the disclosed financing amount has reached more than 260 billion yuan.
Under the catalysis of policies, technologies, and capital, the R&D and innovation strength of the biopharmaceutical industry has steadily increased, and the scale has accelerated. Data from the National Bureau of Statistics shows that in 2020, the market size of my country’s biopharmaceutical industry will reach 3.57 trillion yuan, a year-on-year increase of 8.51%. It is expected to exceed 4 trillion yuan in 2022.
Post time: May-20-2022